Abstract: Permutation entropy (PE) is a widely used metric for quantifying the complexity of time series data. Recent efforts have extended PE to graph signals, resulting in the graph permutation ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Recursive, agent-driven intelligence promises extraordinary gains, but it also introduces risks that scale faster than human oversight, governance, and intuition. The challenge ahead is not whether ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

In my book, Spoiled, I engage with a group of contemporary Asian American artists who expose and unravel the expectation that their work should heal and repair the wounds of racial difference as ...

Getting ready for coding interviews can feel like a big task, and figuring out the best way to tackle LeetCode is a common question. Many people find that using Python for their LeetCode solutions ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

After thinking through it I think I get it more (recursion is hard to wrap your head around), so I'm not sure if this is an issue or not, but possibly could use a bit more clarity for newbies like me ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...